COLUMBUS, Ohio, Aug. 23 /PRNewswire/ -- Ventaira Pharmaceuticals, Inc. announced today that the Company has appointed Lex Adjei, Ph.D. as Vice President, Research and Development.
Dr. Adjei joins Ventaira with more than 20 years of experience in research and development in the pharmaceutical industry. Most recently, he served as the Vice President of Research and Development with KOS Pharmaceuticals where he was responsible for formulation development and device support for the company’s inhaled asthma and diabetes franchises. In this role, Dr. Adjei led the creation and approval of 32 USPTO aerosol formulation and device technologies, and developed best standards to guide systemic aerosol formulation development of protein drugs. Prior to KOS, Dr. Adjei spent time at Abbott Laboratories where he directed the development and commercial manufacture of Lupron Mist(R), the first injectable peptide filed as a noninvasive aerosol. Dr. Adjei is the co-author of the book, Inhalation Delivery of Therapeutic Peptides and Proteins, and he is a member of the International Symposium on Aerosols in Medicine, the American Association of Pharmaceutical Sciences and the AAPS Aerosol Program Committee, Pharmaceutical Technology Section. He received a Ph.D. and an M.S. in pharmaceutical science and a B.S. in pharmacy from The University of Texas at Austin.
“Dr. Adjei’s experience with reformulation of proteins and peptides for pulmonary delivery will be instrumental as we continue to explore delivery of these types of molecules with our commercial inhaler,” stated Leslie Williams, President and CEO of Ventaira Pharmaceuticals. “Dr. Adjei, along with the other members of our product development team, will be instrumental in moving our clinical program forward and identifying additional products to meet the unmet needs of patients in the rapidly expanding inhalation market.”
About Ventaira Pharmaceuticals
Ventaira is a specialty pharmaceutical company that uses its proprietary pulmonary drug delivery technology, Mystic(TM) ((Electrohydrodynamic EHD), and formulation capabilities to deliver respiratory and systemically active drugs more efficiently and effectively. Ventaira is currently developing its own proprietary drugs for the treatment of a wide variety of conditions and also looks to create opportunities for existing drugs that may be more easily delivered via inhalation. Ventaira has an exclusive license on a portfolio of patents for its Mystic technology.
Ventaira Pharmaceuticals, Inc.
CONTACT: Leslie Williams, President & CEO of Ventaira Pharmaceuticals,+1-614-340-2338; or Susan Neath, Media & Investors, of Porter Novelli LifeSciences, +1-619-849-6007
Web site: http://www.ventaira.com/
